Analysts’ Recent Ratings Updates for Kymera Therapeutics (KYMR)

Several analysts have recently updated their ratings and price targets for Kymera Therapeutics (NASDAQ: KYMR):

• 10/8/2026 – Kymera Therapeutics is now covered by Raymond James Financial, Inc.. They set an “outperform” rating and a $140.00 price target on the stock.
• 10/5/2026 – Kymera Therapeutics had its price target raised by Citigroup Inc. from $135.00 to $150.00. They now have a “buy” rating on the stock.
• 9/23/2026 – Kymera Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $140.00 price target on the stock.
• 9/22/2026 – Kymera Therapeutics had its price target raised by Stifel Nicolaus from $132.00 to $152.00. They now have a “buy” rating on the stock.
• 9/14/2026 – Kymera Therapeutics had its price target raised by Bank of America Corporation from $123.00 to $144.00. They now have a “buy” rating on the stock.
• 9/10/2026 – Kymera Therapeutics was upgraded by Wolfe Research from “peer perform” to “outperform”. They now have a $180.00 price target on the stock.
• 8/31/2026 – Kymera Therapeutics had its price target raised by Guggenheim from $135.00 to $170.00. They now have a “buy” rating on the stock.
• 8/27/2026 – Kymera Therapeutics had its price target raised by Wells Fargo & Company from $116.00 to $151.00. They now have an “overweight” rating on the stock.
• 8/24/2026 – Kymera Therapeutics was upgraded by TD Cowen to “strong-buy”.

Insiders Place Their Bets

In related news, CEO Nello Mainolfi sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the completion of the sale, the chief executive officer owned 666,568 shares of the company’s stock, valued at $75,855,438.40. This trade represents a 4.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Brian Adams sold 6,371 shares of the stock in a transaction on Friday, September 4th. The shares were sold at an average price of $116.83, for a total value of $744,323.93. Following the sale, the insider owned 50,254 shares in the company, valued at approximately $5,871,174.82. This represents a 11.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 15.98% of the stock is currently owned by insiders.

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively remove disease-causing proteins from cells. The company uses its targeted protein degradation platform, including molecular glue degraders, to address proteins that may be difficult to inhibit with conventional small-molecule drugs.

Kymera’s research and development activities center on immune-inflammatory diseases and cancer. Its pipeline has included investigational degraders designed to target proteins such as interleukin-1 receptor-associated kinase 4 (IRAK4) and signal transducer and activator of transcription 6 (STAT6), with the goal of treating conditions involving abnormal immune signaling.